ArriVent BioPharma, Inc. Overview
Pro stress-test →ArriVent BioPharma is a clinical-stage biopharmaceutical company engaged in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company focuses on oncology therapeutics with strategic collaborations spanning China and North America.
Strategic Profile
Pro stress-test →The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor being evaluated in multiple clinical trials across epidermal growth factor receptor mutations in non-small cell lung cancer, including Phase 3 trials for exon 20 insertion mutations and Phase 1b trials for PACC mutations. Firmonertinib has received both Breakthrough Therapy and Orphan Drug Designations from the FDA.
Competitive Landscape
Pro stress-test →The company specializes in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer and other solid tumors. ArriVent competes in a dynamic EGFR TKI and ADC therapeutic space with differentiation through novel mutation targeting and brain penetrance in firmonertinib.
Industry Context
ArriVent BioPharma, Inc. operates in Biopharmaceuticals - Oncology Therapeutics.
Key facts
Founded: 2021 · Headquarters: Newtown Square, Pennsylvania, United States · Market cap: $855.4M